Accueil > Actualité
Actualite financiere : Actualite bourse

AstraZeneca: positive results in breast cancer

( - On Monday AstraZeneca announced that Enhertu, the antibody-conjugate that it is developing with Japan's Daiichi Sankyo, has shown positive results in a trial of patients with advanced breast cancer.

The biopharmaceutical company says the phase III study met its primary endpoint by significantly improving (both clinically and statistically) the duration of progression-free survival in patients.

The trial's secondary endpoint, i.e. improvement in overall patient survival, was also met.

The trial, dubbed "Destiny-Breast02", compared the efficacy of Enhertu against a physician-preferred treatment of choice for HER2-positive, non-operable and/or metastatic breast cancer in patients already treated with Roche's Kadcyla.

AstraZeneca plans to present this data at an upcoming medical meeting.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.